Related by context. All words. (Click for frequent words.) 69 hepatectomy 69 locoregional recurrence 69 kidney transplant recipients 68 nondiabetic patients 68 retrospective cohort 68 β blockers 68 pretransplant 68 perioperatively 68 thrombocytopenic 68 coinfected patients 67 HSCT 67 recurrent glioblastoma multiforme 67 prostate cancer CaP 67 renal transplantation 67 rFVIIa 67 histologically confirmed 67 relapsed MM 67 baseline LDH 67 symptomatic VTE 67 angiographically 67 NMIBC 67 IPAH 67 subgroup analyzes 66 serum lipid levels 66 5-fluorouracil/leucovorin 66 paricalcitol 66 MGUS 66 renal tumors 66 fluvastatin 66 KRAS status 66 ximelagatran 66 patients undergoing CABG 66 hemodialysis patients 66 STRIDE PD 66 genotypic resistance 66 prospectively defined 66 hepatorenal syndrome 66 beta blocker therapy 66 pancreatectomy 66 histological subtype 66 colorectal adenoma 66 randomized controlled trials RCTs 66 allogeneic bone marrow 66 Doxil ® 66 eplerenone 66 thromboembolic complications 66 CYPHER Stent 65 posttransplant 65 pCR 65 prospective multicenter study 65 Subgroup analysis 65 HBeAg negative 65 HER2 expression 65 postoperative mortality 65 adjuvant tamoxifen 65 adjuvant radiotherapy 65 HIV HCV coinfected 65 thromboprophylaxis 65 retransplantation 65 myocardial infarctions MIs 65 retrospective cohort study 65 perioperative mortality 65 underwent CABG 65 cranial irradiation 65 mycophenolate mofetil 65 leukemia AML 65 LV dysfunction 65 locoregional 65 biochemical recurrence 65 elevated triglyceride levels 65 hepatic resection 65 unstable angina pectoris 65 adrenalectomy 65 liver histology 65 liver resection 65 perioperative morbidity 64 renal cell carcinomas 64 BEXXAR Therapeutic Regimen 64 antiretroviral naïve 64 coronary revascularization 64 multivariable analysis 64 glomerular filtration 64 Subgroup analyzes 64 postoperative complication 64 multivariate analyzes 64 NATRECOR ® 64 allogeneic transplant 64 virologic failure 64 allogeneic HSCT 64 CsA 64 NSTE ACS 64 tumor histology 64 perioperative complications 64 Immunosuppression 64 advanced adenomas 64 recurrent VTE 64 operable breast cancer 64 preoperative chemotherapy 64 noncardiac 64 liver transplantations 64 thromboembolism 64 Adjuvant therapy 64 K ras mutations 64 transplantation HSCT 64 endometrial carcinoma 64 pancreatic adenocarcinoma 64 MELD scores 64 decompensated cirrhosis 64 abacavir Ziagen 64 seropositivity 64 papillary renal cell carcinoma 64 neoadjuvant 64 antigen PSA levels 64 echocardiographic parameters 64 unresectable tumors 64 LDLT 64 neoadjuvant therapy 64 distant metastases 64 histologically proven 64 HBeAg positive patients 64 allogeneic hematopoietic stem cell 64 SSc 64 cytoreductive surgery 64 vertebral fracture 64 VTE prophylaxis 64 advanced adenoma 64 riociguat 64 NHANES III 64 randomized multicenter trial 64 urothelial cancer 64 periprocedural 64 HORIZONS AMI trial 64 radioiodine therapy 64 Radical prostatectomy 64 univariate analyzes 64 CTEPH 64 renal transplants 63 thromboembolic events 63 pelvic lymphadenectomy 63 immunosuppressive regimen 63 prostate cancer PCa 63 multicenter study 63 reinfarction 63 underwent surgical resection 63 carotid artery stenting CAS 63 hepatic metastases 63 antiplatelet drugs 63 hsCRP levels 63 atherogenic dyslipidemia 63 ATACAND 63 seminomas 63 urolithiasis 63 SORT OUT III 63 underwent liver transplantation 63 carotid stenosis 63 graft dysfunction 63 allogeneic stem cell 63 nonvertebral fracture 63 ischemic cardiomyopathy 63 ELBW infants 63 stage IIIb IV 63 cirrhotic patients 63 PROSTVAC VF 63 liver metastasis 63 SLNB 63 renal biopsy 63 transrectal ultrasound guided 63 breast carcinoma 63 ABCB1 63 Kaplan Meier analysis 63 glycated hemoglobin levels 63 undergone radical prostatectomy 63 portal vein thrombosis 63 cinacalcet 63 lipid lowering therapy 63 neoadjuvant treatment 63 aortic insufficiency 63 nulliparous women 63 peritoneal cancer 63 RE LY ® 63 artery stenosis 63 cerebral microbleeds 63 nodal metastasis 63 stage IIIB 63 antibody titer 63 carotid IMT 63 onset atrial fibrillation 63 metastatic neuroendocrine tumors 63 distant metastasis 63 Adjuvant chemotherapy 63 coronary calcification 63 myocardial infarctions 63 LHRH receptor positive 63 aldosterone antagonist 63 definite stent thrombosis 63 everolimus eluting stents 63 bypass grafting 63 recurrent venous thromboembolism 63 radical nephrectomy 63 mg/m2 dose 63 esophagectomy 63 biochemical relapse 63 NNRTI resistance 63 prostate carcinoma 63 underwent resection 63 CC genotype 63 tumor recurrence 63 histologic subtype 63 Related Mortality 63 nonalcoholic steatohepatitis NASH 63 neoadjuvant chemotherapy 63 CVD mortality 63 androgen suppression 63 nonpregnant women 63 serous ovarian cancer 63 hepatocellular carcinomas 63 autologous SCT 63 atherosclerotic renal artery stenosis 63 polyp recurrence 63 adverse cytogenetics 63 BRCA2 mutation carriers 63 tipranavir ritonavir 62 homocysteine concentrations 62 morphometric vertebral fractures 62 intracranial hemorrhage ICH 62 graft occlusion 62 elevated ALT 62 revascularization procedures 62 virological response 62 undetectable HBV DNA 62 thrombotic complications 62 antitumor effect 62 RRMS patients 62 HNSCC 62 salpingo oophorectomy 62 Renal Cell Carcinoma RCC 62 galiximab 62 HBeAg 62 alteplase 62 T1DM 62 ECD kidneys 62 revascularization procedure 62 chemoprevention trials 62 operable pancreatic cancer 62 colorectal neoplasia 62 CSF biomarkers 62 irbesartan 62 Carotid Revascularization Endarterectomy vs. 62 atherothrombosis 62 drug eluting stent implantation 62 mutated K ras 62 HCV SPRINT 62 prospective observational 62 randomized trials 62 renal transplant 62 chronic GVHD 62 postoperative radiotherapy 62 colorectal liver metastases 62 prognostic variables 62 seronegative 62 nonfatal MI 62 OPCAB 62 serum GGT 62 esophageal squamous cell carcinoma 62 ß blockers 62 Microalbuminuria 62 cardiac dysfunction 62 pheochromocytoma 62 ADPKD 62 poor metabolizers 62 variceal bleeding 62 Avandia Actos 62 prospective multicentre 62 lung resection 62 ertapenem 62 oncologic outcomes 62 BARACLUDE ® 62 postoperative morbidity 62 Cystatin C 62 cerebral angiography 62 rt PA 62 nonischemic 62 flutamide 62 trials RCTs 62 nonvertebral fractures 62 undergoing coronary angiography 62 systolic dysfunction 62 HCV infected 62 fosamprenavir 62 NATRECOR R 62 oral Hycamtin 62 % CI #.#-#.# [003] 62 metastatic RCC 62 femoral neck fracture 62 serum selenium 62 cystectomy 62 ALT flares 62 candidemia 62 recurrent GBM 62 dosage regimens 62 hematologic toxicity 62 antidiabetic medication 62 chlamydial infection 62 T2DM 62 pulmonary metastases 62 urothelial carcinoma 62 lymphocyte count 62 posaconazole 62 postoperative chemotherapy 62 chorioamnionitis 62 metastatic renal cell carcinoma 62 observational cohort 62 squamous cell lung cancer 62 monoclonal gammopathy 62 multicentre study 62 ExTRACT TIMI 62 EXJADE 62 conjugated equine estrogen 62 nodal metastases 62 immunosuppression therapy 62 CMV infection 62 ZACTIMA 62 clinicopathologic 62 IgA deficiency 62 hematological parameters 62 extrapleural pneumonectomy 62 posttreatment 62 KRAS mutation 62 nadroparin 62 basal cell carcinoma BCC 62 taxane therapy 62 NSABP B 62 HIV uninfected 62 observational cohort study 62 hA# 62 neurologic complications 62 chemoradiotherapy 62 sleeve lobectomy 62 total thyroidectomy 62 debulking surgery 62 dose cohort 62 multivariate logistic regression 62 CALGB 62 intravesical therapy 62 obstructive coronary artery 62 serum concentrations 62 allogeneic transplants 62 oral anticoagulation 62 olmesartan 62 hepatitis C genotype 62 logistic regression analysis 62 transfusion syndrome 62 stratifying patients 62 protease inhibitor PI 62 carcinoid 62 subanalysis 61 myeloablative 61 dysglycemia 61 serum calcium levels 61 gallstone disease 61 resected pancreatic cancer 61 postintervention 61 EGFR mutation status 61 invasive candidiasis 61 triglyceride concentrations 61 lung metastases 61 coinfection 61 KRAS mutations occur 61 transient elastography 61 leiomyomas 61 Thal Dex 61 vaginal hysterectomy 61 malignant lymphoma 61 warfarin therapy 61 MGd 61 strontium ranelate 61 pegylated liposomal doxorubicin 61 Lung transplantation 61 carotid plaque 61 candesartan cilexetil 61 Stent thrombosis 61 axillary lymph nodes 61 nephrolithiasis 61 serum creatinine levels 61 PSADT 61 gastrectomy 61 nephron sparing surgery 61 umol L 61 Coronary Artery Bypass Graft 61 clinico pathological 61 bezafibrate 61 pericardial effusion 61 atherothrombotic disease 61 mycophenolate mofetil MMF 61 transplantation HCT 61 prospective longitudinal 61 colorectal carcinoma 61 tirofiban 61 malignant neoplasm 61 prospective cohort 61 intracerebral hemorrhage 61 Atypical Hemolytic Uremic Syndrome 61 CR nPR 61 chest radiographs 61 antithrombotic therapy 61 VADT 61 gestational hypertension 61 timepoints 61 beta carotene supplementation 61 FluCAM arm 61 Circulating tumor cells 61 hemorrhagic complications 61 troponins 61 postoperative complications 61 nonoperative treatment 61 specific antigen PSA 61 renal allograft 61 eosinophil count 61 allogeneic transplantation 61 TNF antagonist 61 SSc patients 61 cell carcinomas 61 HoFH 61 Complication rates 61 virologic response 61 ARIXTRA 61 euthyroid 61 HER2 overexpression 61 autologous hematopoietic stem cell 61 prognostic significance 61 prospectively randomized 61 unstable angina UA 61 APOL1 61 hematopoietic cancers 61 macrovascular disease 61 duplex ultrasonography 61 glomerular filtration rate 61 Randomized Study 61 null responder 61 MACCE 61 hepatocellular carcinoma HCC 61 androgen deprivation 61 HGPIN 61 endometrial hyperplasia 61 immunosuppressive medications 61 symptomatic intracerebral hemorrhage 61 pancreatic resection 61 gastric adenocarcinoma 61 cytoreduction 61 thromboembolic disease 61 lymphocytosis 61 IV NSCLC 61 Univariate analysis 61 CHAMPION PCI 61 platelet reactivity 61 multicenter randomized controlled 61 HBeAg seroconversion 61 parathyroidectomy 61 kidney allograft 61 sirolimus eluting stents 61 HCV genotype 61 virologic responses 61 multivariable analyzes 61 PLCO 61 intestinal metaplasia 61 acute myocardial infarction MI 61 pneumonectomy 61 BRCA1 mutations 61 carotid artery stenting 61 randomized controlled clinical trials 61 thromboembolic 61 latent celiac disease 61 complete cytogenetic response 61 metabolic parameters 61 radiotherapy RT 61 elevated LDH 61 heavily pretreated patients 61 ritonavir boosted 61 XIENCE V PROMUS Stent 61 Hazard Ratio 61 pT3 61 Neoadjuvant 61 certolizumab 61 malignant pleural mesothelioma 61 eculizumab therapy 61 multicentre prospective 61 preintervention 61 LVNC 61 ARCOXIA 61 QTc prolongation 61 virologic breakthrough 61 serum aminotransferase levels 61 Coronary artery bypass grafting 61 interferon ribavirin 61 bovine thrombin 61 HYVET 61 DES implantation 61 angiographic outcomes 61 intravenous bisphosphonates 61 multiple logistic regression 61 BRCA mutation carriers 61 5q deletion 61 PSA nadir 61 subclinical hypothyroidism 61 antiretroviral naive 61 HbA 1c levels 61 Natalizumab 61 logistic regression analyzes 61 pulmonary artery banding 61 Randomized Evaluation 61 HBeAg negative patients 61 acetabular dysplasia 61 PTLD 61 patients evaluable 61 colectomy 61 MADIT II 61 octreotide LAR 61 subtrochanteric 61 cancer mCRC 61 ImmuKnow assay 61 pancreatic neuroendocrine tumors 61 univariate analysis 61 prognostic factors 61 PRADAXA 61 Events MACE 61 antihypertensive therapy 61 symptomatic intracranial 61 pamidronate 61 haematopoietic stem cell 61 pyelonephritis 61 hormone receptor status 61 bladder carcinoma 61 IFN beta 61 pediatric acute lymphoblastic 61 MADIT CRT trial 61 prospective observational cohort 61 APTIVUS r 61 tumor necrosis 61 supratentorial 61 carotid plaques 61 Estrogen Receptor 61 LNG IUS 61 heavily pretreated 61 TNF blocker therapy 61 thrombotic events 61 nephrotoxicity 61 serum urate levels 61 longitudinal cohort study 61 AA Amyloidosis 61 allogeneic SCT 61 plasma pharmacokinetics 61 MAGE A3 ASCI 61 IFN alfa 61 osteoporotic vertebral compression fractures 61 periprocedural MI 61 antiangiogenic therapy 61 paclitaxel eluting stents 61 Thrombolysis 61 elevated serum creatinine 61 relapsing remitting MS RRMS 61 micafungin 61 clot busting therapy 61 antioxidant supplementation 61 APTIVUS 61 inhaled corticosteroid therapy 61 Intervention Trial 60 radical retropubic prostatectomy 60 FOLFIRINOX 60 APTIVUS R 60 TEAEs 60 placebo dexamethasone 60 thrombolytic therapy 60 enzyme elevations 60 cytoreductive nephrectomy 60 invasive ductal 60 troponin T 60 metastatic malignant 60 edifoligide 60 dose escalation phase 60 gadolinium enhanced 60 imatinib therapy 60 cutaneous melanoma 60 squamous histology 60 multivessel disease 60 underwent radical prostatectomy 60 GH deficiency 60 nonrandomized 60 carcinoid tumors 60 cervical lymph nodes 60 thyrotropin levels 60 platelet inhibitor 60 plasma folate 60 PCa 60 PROSTVAC ® 60 hemodilution 60 remission CR 60 deep venous thromboses 60 aortic root replacement 60 chronic thromboembolic pulmonary 60 reperfusion therapy 60 Stenting Trial CREST 60 intensive statin therapy 60 TMP SMX 60 gefitinib Iressa 60 Acute Decompensated Heart Failure 60 intravenous diuretics 60 acute humoral rejection 60 pretreatment serum 60 clinically localized prostate 60 silent ischemia 60 KRAS mutations 60 hemodynamically significant 60 Multivariate analysis 60 Proteinuria 60 basal cell nevus syndrome 60 systolic hypertension 60 recurrent UTI 60 radical cystectomy 60 HeFH 60 hypercholesterolemic patients 60 calculated creatinine clearance 60 N telopeptide 60 cerebral vasospasm 60 adiponectin concentrations 60 hepatic arterial 60 Femara letrozole 60 ICD implantation 60 atrophic gastritis 60 preserved ejection fraction 60 stable angina 60 reoperations 60 Amrubicin 60 preterm newborns 60 HBsAg 60 obese postmenopausal 60 therapeutic regimens 60 EMPHASIS HF trial 60 serum calcium 60 tenecteplase 60 singleton pregnancies 60 dose atorvastatin 60 nondiabetics 60 hyperacute 60 ejection fractions 60 mCRC patients 60 prostate cancer CRPC 60 Critical Limb Ischemia CLI 60 intravenous cyclophosphamide 60 placebo controlled studies 60 LEXIVA r 60 progression TTP 60 STEP BD 60 postoperative AF 60 aminotransferases 60 Skin sterol 60 fibrinolytic therapy 60 Baseline characteristics 60 treatment naïve genotype 60 neutrophil counts 60 GnRH agonists 60 URTI 60 inflammatory rheumatic 60 serum PSA 60 Cardiopulmonary bypass 60 ribavirin therapy 60 thyroid nodules 60 tHcy 60 completely resected 60 dalteparin 60 unresectable HCC 60 Logistic regression 60 baseline HbA1c 60 hypercalciuria 60 cilostazol 60 placebo controlled clinical trials 60 RCTs 60 intraoperative complications 60 mucinous 60 estramustine 60 clevidipine 60 inflammatory biomarkers 60 Asymptomatic 60 sirolimus stent 60 RE LY trial 60 retrospective observational study 60 mutated KRAS 60 scintigraphic 60 aspirin clopidogrel 60 PNH patients 60 neurodevelopmental impairment 60 transaminase levels 60 CLL SLL 60 revascularisation 60 de novo AML 60 neurologic progression 60 cytogenetic responses 60 clazosentan 60 invasive fungal infection 60 RECIST Response Evaluation Criteria 60 composite endpoint 60 CYP#D# genotype 60 autonomic dysfunction 60 F FDG PET 60 calcineurin inhibitor 60 abacavir lamivudine 60 iodixanol 60 bacterial prostatitis 60 LHRH agonists 60 NOMID 60 doxorubicin docetaxel 60 TroVax ® 60 FOLPI 60 EOquin TM 60 myelodysplastic myeloproliferative diseases 60 dose statin therapy 60 chemoradiation therapy 60 CMV disease 60 recurrent ischemia 60 dyslipidaemia 60 CYP#D# inhibitor 60 BARI 2D 60 placebo controlled trials 60 albumin excretion rate 60 undergoing coronary artery 60 multicenter trials 60 malignant neoplasms 60 psychiatric outpatients 60 BENICAR HCT 60 autologous transplants 60 longitudinal observational study 60 node metastases 60 curative resection 60 CIN3 60 metastatic gastric 60 p# biomarker 60 clinically evaluable 60 cirrhotic 60 nonmetastatic 60 fasting glucose levels 60 lymphadenectomy 60 Genotypes 60 carotid artery blockage 60 liver metastases 60 Naive Patients 60 nonfasting triglyceride levels 60 immunohistochemical staining 60 refractory CLL 60 comparator arm 60 patientswith 60 hypertensive patients 60 liver transplantation 60 hydroxyvitamin D levels 60 cystatin C 60 invasive aspergillosis 60 adenomatous 60 extramedullary 60 Malignant Melanoma 60 syngeneic 60 del 5q 60 hepatic fibrosis 60 chronic HBV 60 SCr 60 PAOD 60 polytherapy 60 Nilotinib 60 thrombophilia 60 allogeneic hematopoietic cell 60 ipsilateral stroke 60 SCIg 60 dexmedetomidine 60 mammographic density 60 recurrent miscarriage 60 genetic variants associated 60 CTAP# Capsules 60 infective endocarditis 60 EURIDIS 60 carotid revascularization 60 testosterone supplementation 60 Candesartan 60 serum vitamin D 60 Stage IIIb 60 left ventricular dysfunction 60 Hydroxyurea 60 randomized multicenter 60 plasma renin activity 60 caspofungin 60 anagrelide 60 postmenopausal osteoporotic women 60 TDF FTC 60 elevated CRP 60 creatinine levels 60 platelet inhibition 60 recurrent DVT 60 randomized clinical 60 gemcitabine carboplatin 60 noncardiac surgery 60 daily subcutaneous injections 60 salmeterol fluticasone propionate 60 postoperative infection 60 ALND 60 estimated glomerular filtration 60 hypertensives 60 alanine aminotransferase ALT 60 chemotherapeutic regimens 60 elacytarabine 60 HAART regimen 60 neurocognitive impairment 60 Liver transplantation 60 differentiated thyroid 60 non valvular atrial 60 aminotransferase 60 microsatellite instability 60 Parathyroid Hormone 60 Lp PLA 2 60 mixed hyperlipidemia 60 lung adenocarcinomas 60 upper gastrointestinal bleeding 60 SHPT 60 PROactive study 60 thymectomy 60 cTnI 60 ritonavir boosted lopinavir 60 IL#B 59 SYNTAX trial 59 relapsed ALL 59 visceral metastases 59 Cardiotoxicity 59 postoperative atrial fibrillation 59 Flu Cy 59 clinicopathological 59 genetic polymorphisms 59 decompensated heart failure 59 HMG CoA reductase inhibitors 59 intact parathyroid hormone 59 chlorambucil 59 pilocytic astrocytomas 59 TAXUS Stent 59 low expressors 59 adjuvant therapies 59 empyema 59 HRQL 59 resected tumors 59 lumiracoxib 59 serum estradiol 59 Endometrial 59 hyperoxaluria 59 Vidaza azacitidine 59 RBC folate 59 surgically resected 59 Randomized trials 59 grade cervical intraepithelial 59 d4T stavudine Zerit 59 RSD# oral 59 randomized multicenter Phase III 59 BCIRG 59 CCyR 59 Chronic lymphocytic leukemia 59 CIMZIA ™ 59 lipid lowering agents 59 fibrinolytic 59 severe exacerbations 59 oesophageal adenocarcinoma 59 idiopathic pulmonary arterial hypertension 59 Kaplan Meier estimate 59 cardiovascular morbidity 59 alkaline phosphatase ALP 59 confidence interval #.#-#.# 59 prophylactic cranial irradiation 59 urate levels 59 antihypertensive medication 59 Coronary artery bypass graft 59 multivariate Cox 59 androgen suppression therapy 59 chemoradiation 59 Hematologic 59 revascularizations 59 XELOX 59 latent tuberculosis infection 59 intra abdominal abscess 59 prospectively enrolled 59 anti JCV antibodies 59 UGT#A# * 59 macroalbuminuria 59 testicular germ cell 59 deletion 5q 59 coronary blockages 59 pharmacokinetics PK 59 Ranolazine 59 ToGA 59 logistic regression model 59 evaluable patients 59 Erythropoietic therapies may 59 catheter angiography 59 NNT = 59 fibrinolysis 59 persistent pulmonary hypertension 59 tigecycline 59 metastatic lesions 59 pretest probability 59 familial clustering 59 ACTEMRA TM 59 C. trachomatis 59 Chronic pancreatitis 59 del 5q MDS 59 conditional logistic regression 59 neurological manifestations 59 canakinumab 59 Kaplan Meier curve 59 Elitek 59 Postmenopausal 59 CIMZIA TM certolizumab pegol 59 fragility fracture 59 iniparib BSI 59 anthracycline therapy 59 INCB# [003] 59 Cognitive impairment 59 colorectal cancer incidence 59 PREZISTA r 59 leukocyte count 59 tibolone 59 EGFR mutation positive 59 TIMP 59 ICD therapy 59 bronchogenic carcinoma 59 venous thromboembolic disease 59 Epidemiologic studies 59 clodronate 59 candesartan 59 cerebral infarction 59 metastatic GIST 59 gonococcal infections 59 #F FDG PET 59 DAPT 59 mg kg dose 59 coronary artery occlusion 59 splenectomized patients 59 gastric cardia 59 immunochemical fecal occult 59 spirometric 59 CIN2 + 59 haemorrhagic stroke 59 solifenacin 59 carotid endarterectomy CEA 59 adenoma recurrence 59 ImmuKnow 59 HBeAg positive 59 cardiac repolarization 59 recurrent metastatic 59 advanced neoplasia 59 arteriography 59 serum triglycerides 59 ruboxistaurin 59 sorafenib Nexavar 59 occlusive disease 59 esophageal carcinoma 59 aromatase inhibitor therapy 59 HCV RESPOND 2 59 Certican 59 ACUITY trial 59 coronary stenosis 59 nonmetastatic prostate cancer 59 #mg BID [003] 59 metastatic bladder 59 triacylglycerol concentrations 59 TMC# r 59 smoldering myeloma 59 PsA 59 intracerebral haemorrhage 59 childhood acute lymphoblastic 59 antithrombotic agents 59 alemtuzumab treated 59 histologies 59 Postoperative complications 59 lymph node metastases 59 telomere lengths 59 hormone receptor negative 59 rebleeding 59 resynchronization therapy 59 hyperphenylalaninemia HPA due 59 lupus nephritis 59 Ischemic 59 evaluable subjects 59 sonographic diagnosis 59 NGAL 59 GRASPA ® 59 S. maltophilia 59 atazanavir 59 prognostic markers 59 Prostate Lung Colorectal 59 pain palliation 59 invasive ductal breast cancer 59 ER CHOP 59 Non Alcoholic Steatohepatitis 59 adenotonsillectomy 59 HIV seronegative 59 receptor tyrosine kinase inhibitor 59 Hepatocellular Carcinoma HCC 59 Chronic Myelogenous Leukemia CML 59 paroxysmal AF